{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T01:32:49Z","timestamp":1781487169956,"version":"3.54.1"},"reference-count":29,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004504","name":"Research Council of Lithuania","doi-asserted-by":"publisher","award":["S-SEN-20-2"],"award-info":[{"award-number":["S-SEN-20-2"]}],"id":[{"id":"10.13039\/501100004504","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Acute myeloid leukemia is the second most frequent type of leukemia in adults. Due to a high risk of development of chemoresistance to first-line chemotherapy, the survival rate of patients in a 5-year period is below 30%. One of the reasons is that the AML population is heterogeneous, with cell populations partly composed of very primitive CD34+CD38- hematopoietic stem\/progenitor cells, which are often resistant to chemotherapy. First-line treatment with cytarabine and idarubicin fails to inhibit the proliferation of CD34+CD38- cells. In this study, we investigated Metformin\u2019s effect with or without first-line conventional chemotherapy, or with other drugs like venetoclax and S63845, on primitive and undifferentiated CD34+ AML cells in order to explore the potential of Metformin or S63845 to serve as adjuvant therapy for AML. We found that first-line conventional chemotherapy treatment inhibited the growth of cells and arrested the cells in the S phase of the cell cycle; however, metformin affected the accumulation of cells in the G2\/M phase. We observed that CD34+ KG1a cells respond better to lower doses of cytarabine or idarubicin in combination with metformin. Also, we determined that treatment with cytarabine, venetoclax, and S63845 downregulated the strong tendency of CD34+ KG1a cells to form cell aggregates in culture due to the downregulation of leukemic stem cell markers like CD34 and CD44, as well as adhesion markers. Also, we found that idarubicin slightly upregulated myeloid differentiation markers, CD11b and CD14. Treatment with cytarabine, idarubicin, venetoclax, metformin, and S63845 upregulated some cell surface markers like HLA-DR expression, and metformin upregulated CD9, CD31, and CD105 cell surface marker expression. In conclusion, we believe that metformin has the potential to be used as an adjuvant in the treatment of resistant-to-first-line-chemotherapy AML cells. Also, we believe that the results of our study will stimulate further research and the potential use of changes in the expression of cell surface markers in the development of new therapeutic strategies.<\/jats:p>","DOI":"10.3390\/genes15050648","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T03:26:27Z","timestamp":1716261987000},"page":"648","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metformin as an Enhancer for the Treatment of Chemoresistant CD34+ Acute Myeloid Leukemia Cells"],"prefix":"10.3390","volume":"15","author":[{"given":"Indre","family":"Krastinaite","sequence":"first","affiliation":[{"name":"Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Sauletekio Av. 7, LT-10257 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergej","family":"Charkavliuk","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Sauletekio Av. 7, LT-10257 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1077-9439","authenticated-orcid":false,"given":"Ruta","family":"Navakauskiene","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Sauletekio Av. 7, LT-10257 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6077-0136","authenticated-orcid":false,"given":"Veronika Viktorija","family":"Borutinskaite","sequence":"additional","affiliation":[{"name":"Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Sauletekio Av. 7, LT-10257 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: Prognostic and Therapeutic Implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/joim.13293","article-title":"Acute Myeloid Leukaemia in Patients We Judge as Being Older and\/or Unfit","volume":"290","author":"Lazarevic","year":"2021","journal-title":"J. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Garciaz, S., Hospital, M.-A., Collette, Y., and Vey, N. (2024). Venetoclax Resistance in Acute Myeloid Leukemia. Cancers, 16.","DOI":"10.3390\/cancers16061091"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3324\/haematol.2020.260331","article-title":"Targeting MCL-1 Dysregulates Cell Metabolism and Leukemia-Stroma Interactions and Resensitizes Acute Myeloid Leukemia to BCL-2 Inhibition","volume":"107","author":"Carter","year":"2022","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"111027","DOI":"10.1016\/j.cellsig.2023.111027","article-title":"The Roles and Mechanisms of TGFB1 in Acute Myeloid Leukemia Chemoresistance","volume":"116","author":"Liang","year":"2024","journal-title":"Cell. Signal."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s12185-017-2221-5","article-title":"Leukemic Stem Cells: Identification and Clinical Application","volume":"105","author":"Hanekamp","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.stem.2018.05.021","article-title":"AMPK\/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells","volume":"23","author":"Pei","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3389\/fendo.2018.00446","article-title":"Metformin, an Anti-Diabetic Drug to Target Leukemia","volume":"9","author":"Biondani","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Patil, S. (2020). Metformin Treatment Decreases the Expression of Cancer Stem Cell Marker CD44 and Stemness Related Gene Expression in Primary Oral Cancer Cells. Arch. Oral. Biol., 113.","DOI":"10.1016\/j.archoralbio.2020.104710"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 Eradicates Human Acute Myeloid Leukemic Stem Cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of Relapsed\/Refractory Acute Myeloid Leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/bmb\/ldaa045","article-title":"Repurposing Approved Drugs for Cancer Therapy","volume":"137","author":"Schein","year":"2021","journal-title":"Br. Med. Bull."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3892\/ol.2012.709","article-title":"The Importance of Molecular Cytogenetic Analysis Prior to Using Cell Lines in Research: The Case of the KG-1a Leukemia Cell Line","volume":"4","author":"Pelliccia","year":"2012","journal-title":"Oncol. Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular Mechanisms of Cell Death: Recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1242\/jcs.114.8.1567","article-title":"N-Cadherin Is Developmentally Regulated and Functionally Involved in Early Hematopoietic Cell Differentiation","volume":"114","author":"Puch","year":"2001","journal-title":"J. Cell Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Skopek, R., Palusi\u0144ska, M., Kaczor-Keller, K., Pingwara, R., Papierniak-Wygl\u0105da\u0142a, A., Schenk, T., Lewicki, S., Zelent, A., and Szyma\u0144ski, \u0141. (2023). Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065377"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood.V92.11.4325","article-title":"Most Acute Myeloid Leukemia Progenitor Cells With Long-Term Proliferative Ability In Vitro and In Vivo Have the Phenotype CD34+\/CD71\u2212\/HLA-DR\u2212","volume":"92","author":"Blair","year":"1998","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Valiulien\u0117, G., Vitkevi\u010dien\u0117, A., Skliut\u0117, G., Borutinskait\u0117, V., and Navakauskien\u0117, R. (2021). Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling. Molecules, 26.","DOI":"10.3390\/molecules26082303"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41375-018-0201-2","article-title":"The MCL1-Specific Inhibitor S63845 Acts Synergistically with Venetoclax\/ABT-199 to Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia Cells","volume":"33","author":"Li","year":"2019","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-00982-3","article-title":"Efficacy and Safety of Cladribine, Low-Dose Cytarabine and Venetoclax in Relapsed\/Refractory Acute Myeloid Leukemia: Results of a Pilot Study","volume":"14","author":"Li","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13148-022-01306-7","article-title":"Chidamide and Venetoclax Synergistically Exert Cytotoxicity on Multiple Myeloma by Upregulating BIM Expression","volume":"14","author":"Cao","year":"2022","journal-title":"Clin. Epigenetics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100972","DOI":"10.1016\/j.currproblcancer.2023.100972","article-title":"Repurposing Metformin in Hematologic Tumor: State of Art","volume":"47","author":"Hu","year":"2023","journal-title":"Curr. Probl. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 Inhibitor S63845 Is Tolerable and Effective in Diverse Cancer Models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood.V68.5.1101.1101","article-title":"Divergent Molecular Phenotypes of KG1 and KGla Myeloid Cell Lines","volume":"68","author":"Furley","year":"1986","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.2020006343","article-title":"CD44 Loss of Function Sensitizes AML Cells to the BCL-2 Inhibitor Venetoclax by Decreasing CXCL12-Driven Survival Cues","volume":"138","author":"Yu","year":"2021","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1080\/10428194.2021.1885659","article-title":"Expression Levels of HLA-DR in Acute Myeloid Leukemia: Implications for Antigenicity and Clinical Outcome","volume":"62","author":"Roerden","year":"2021","journal-title":"Leuk. Lymphoma"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/5\/648\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:45:27Z","timestamp":1760107527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/5\/648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["genes15050648"],"URL":"https:\/\/doi.org\/10.3390\/genes15050648","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]}}}